Skip to main content
Fig. 5 | Arthritis Research & Therapy

Fig. 5

From: The T-cell response to SARS-CoV- 2 vaccination persists beyond six months in rheumatoid arthritis patients treated with rituximab

Fig. 5

Correlation between the global spike protein-specific response of CD8 + T cells and SARS-CoV- 2 serology. CD8+ T-cell global activation parameters in patients with RA treated with RTX (n = 51) are expressed as a function of their SARS-CoV- 2 serology (BAU/mL). The green and red circles show patients who had no history or a history of COVID- 19, respectively, in addition to their vaccination. The red line indicates the linear regression analysis curve

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us